Exacerbation of Autoimmune Hepatitis following Inactivated SARS-CoV-2 Vaccination

Siwanon Nawalerspanya, Kontee Wongseree, P. Sripongpun, N. Chamroonkul, A. Kaewdech
{"title":"Exacerbation of Autoimmune Hepatitis following Inactivated SARS-CoV-2 Vaccination","authors":"Siwanon Nawalerspanya, Kontee Wongseree, P. Sripongpun, N. Chamroonkul, A. Kaewdech","doi":"10.31584/jhsmr.20241030","DOIUrl":null,"url":null,"abstract":"Autoimmune hepatitis (AIH) is a rare condition that has seldom been reported being reactivated by a coronavirus disease 2019 (COVID-19) vaccination, especially from an inactivated vaccine. This report presents the case of a 64-year-old male with quiescent AIH cirrhosis who exhibited jaundice and constitutional symptoms for three days at two weeks following his second dose of an inactivated vaccine. The patient had complied well with a four-year immunosuppressive medication regimen to treat AIH which maintained normalized liver enzymes. He also abstained from using herbal supplements. At his presentation, his liver chemistry showed acute hepatocellular jaundice, with histology revealing active AIH. Following extensive testing, he was diagnosed with an AIH exacerbation triggered by the COVID-19 vaccine. His symptoms improved following treatment with higher doses of immunosuppressive agents. This report underscores the potential effect of the COVID-19 vaccine on reactivating well-controlled AIH. ","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":"38 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Science and Medical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31584/jhsmr.20241030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Autoimmune hepatitis (AIH) is a rare condition that has seldom been reported being reactivated by a coronavirus disease 2019 (COVID-19) vaccination, especially from an inactivated vaccine. This report presents the case of a 64-year-old male with quiescent AIH cirrhosis who exhibited jaundice and constitutional symptoms for three days at two weeks following his second dose of an inactivated vaccine. The patient had complied well with a four-year immunosuppressive medication regimen to treat AIH which maintained normalized liver enzymes. He also abstained from using herbal supplements. At his presentation, his liver chemistry showed acute hepatocellular jaundice, with histology revealing active AIH. Following extensive testing, he was diagnosed with an AIH exacerbation triggered by the COVID-19 vaccine. His symptoms improved following treatment with higher doses of immunosuppressive agents. This report underscores the potential effect of the COVID-19 vaccine on reactivating well-controlled AIH. 
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接种非活性 SARS-CoV-2 疫苗后自身免疫性肝炎加重
自身免疫性肝炎(AIH)是一种罕见的疾病,很少有因接种2019年冠状病毒病(COVID-19)疫苗,尤其是灭活疫苗而重新激活的报道。本报告介绍了一例患有静止性 AIH 肝硬化的 64 岁男性患者,他在接种第二剂灭活疫苗两周后出现黄疸和全身症状,持续三天。该患者在治疗 AIH 的四年免疫抑制药物治疗方案中表现良好,肝酶维持正常。他也没有使用草药补充剂。就诊时,他的肝脏生化指标显示为急性肝细胞性黄疸,组织学检查显示为活动性 AIH。经过大量检查后,他被诊断为因接种 COVID-19 疫苗而引发的 AIH 恶化。在使用更大剂量的免疫抑制剂治疗后,他的症状有所改善。该报告强调了 COVID-19 疫苗对重新激活控制良好的 AIH 的潜在影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
0
审稿时长
14 weeks
期刊最新文献
Hospital Food Waste Trends: A Bibliometric Analysis Effectiveness of a Patient-Family-Shared Care Program on Delaying the Progression of Chronic Kidney Disease in Uncontrolled Type 2 Diabetic Patients: A Quasi-Experimental Study Association between Retinal Morphology and Visual Functions in Eyes with Typical Neovascular Age Related Macular Degeneration: A Pilot Study Association of Online Learning Tools and Students’ Health: A Case Study During the COVID-19 Pandemic Comparative Efficacy of Oxitard Capsules and Immusante Tablets in Early Stages of Oral Submucous Fibrosis - A Randomized Controlled Trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1